AMLX logo

Amylyx Pharmaceuticals, Inc. (AMLX) Cash From Financing

Annual CFF:

$348.00K-$3.19M(-90.18%)
December 31, 2024

Summary

  • As of today, AMLX annual cash from financing is $348.00 thousand, with the most recent change of -$3.19 million (-90.18%) on December 31, 2024.
  • During the last 3 years, AMLX annual cash from financing has fallen by -$158.16 million (-99.78%).
  • AMLX annual cash from financing is now -99.92% below its all-time high of $431.79 million, reached on December 31, 2022.

Performance

AMLX Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherAMLXcash flow metrics

Quarterly CFF:

-$31.00K-$65.69M(-100.05%)
June 1, 2025

Summary

  • As of today, AMLX quarterly cash from financing is -$31.00 thousand, with the most recent change of -$65.69 million (-100.05%) on June 1, 2025.
  • Over the past year, AMLX quarterly cash from financing has dropped by -$58.00 thousand (-214.81%).
  • AMLX quarterly cash from financing is now -100.01% below its all-time high of $232.16 million, reached on December 31, 2022.

Performance

AMLX Quarterly Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherAMLXcash flow metrics

TTM CFF:

$65.82M-$58.00K(-0.09%)
June 1, 2025

Summary

  • As of today, AMLX TTM cash from financing is $65.82 million, with the most recent change of -$58.00 thousand (-0.09%) on June 1, 2025.
  • Over the past year, AMLX TTM cash from financing has increased by +$64.54 million (+5054.35%).
  • AMLX TTM cash from financing is now -84.76% below its all-time high of $431.79 million, reached on December 31, 2022.

Performance

AMLX TTM Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherAMLXcash flow metrics

Cash From Financing Formula

CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities

AMLX Cash From Financing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year-90.2%-214.8%+5054.4%
3Y3 Years-99.8%+96.3%-67.0%
5Y5 Years-47.9%--

AMLX Cash From Financing Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Year-99.9%at low-100.0%at low-84.8%>+9999.0%
5Y5-Year-99.9%at low-100.0%+96.3%-84.8%>+9999.0%
All-TimeAll-Time-99.9%at low-100.0%+96.3%-84.8%>+9999.0%

AMLX Cash From Financing History

DateAnnualQuarterlyTTM
Jun 2025
-
-$31.00K(-100.0%)
$65.82M(-0.1%)
Mar 2025
-
$65.66M(>+9900.0%)
$65.88M(>+9900.0%)
Dec 2024
$348.00K(-90.2%)
$110.00K(+37.5%)
$348.00K(-25.6%)
Sep 2024
-
$80.00K(+196.3%)
$468.00K(-63.4%)
Jun 2024
-
$27.00K(-79.4%)
$1.28M(-51.5%)
Mar 2024
-
$131.00K(-43.0%)
$2.63M(-25.7%)
Dec 2023
$3.54M
$230.00K(-74.1%)
$3.54M(-98.5%)
Sep 2023
-
$889.00K(-35.8%)
$235.47M(+0.4%)
Jun 2023
-
$1.38M(+33.1%)
$234.59M(+1.0%)
DateAnnualQuarterlyTTM
Mar 2023
-
$1.04M(-99.6%)
$232.37M(-46.2%)
Dec 2022
$431.79M(+172.4%)
$232.16M(>+9900.0%)
$431.79M(+116.3%)
Sep 2022
-
$0.00(+100.0%)
$199.63M(0.0%)
Jun 2022
-
-$828.00K(-100.4%)
$199.63M(-1.4%)
Mar 2022
-
$200.46M(>+9900.0%)
$202.45M(+625.1%)
Dec 2021
$158.51M(+238.5%)
-
-
Jun 2021
-
$1.99M(-92.3%)
$27.92M(+7.7%)
Mar 2021
-
$25.93M
$25.93M
Dec 2020
$46.82M(+6909.4%)
-
-
Dec 2019
$668.00K
-
-

FAQ

  • What is Amylyx Pharmaceuticals, Inc. annual cash from financing?
  • What is the all-time high annual cash from financing for Amylyx Pharmaceuticals, Inc.?
  • What is Amylyx Pharmaceuticals, Inc. annual cash from financing year-on-year change?
  • What is Amylyx Pharmaceuticals, Inc. quarterly cash from financing?
  • What is the all-time high quarterly cash from financing for Amylyx Pharmaceuticals, Inc.?
  • What is Amylyx Pharmaceuticals, Inc. quarterly cash from financing year-on-year change?
  • What is Amylyx Pharmaceuticals, Inc. TTM cash from financing?
  • What is the all-time high TTM cash from financing for Amylyx Pharmaceuticals, Inc.?
  • What is Amylyx Pharmaceuticals, Inc. TTM cash from financing year-on-year change?

What is Amylyx Pharmaceuticals, Inc. annual cash from financing?

The current annual cash from financing of AMLX is $348.00K

What is the all-time high annual cash from financing for Amylyx Pharmaceuticals, Inc.?

Amylyx Pharmaceuticals, Inc. all-time high annual cash from financing is $431.79M

What is Amylyx Pharmaceuticals, Inc. annual cash from financing year-on-year change?

Over the past year, AMLX annual cash from financing has changed by -$3.19M (-90.18%)

What is Amylyx Pharmaceuticals, Inc. quarterly cash from financing?

The current quarterly cash from financing of AMLX is -$31.00K

What is the all-time high quarterly cash from financing for Amylyx Pharmaceuticals, Inc.?

Amylyx Pharmaceuticals, Inc. all-time high quarterly cash from financing is $232.16M

What is Amylyx Pharmaceuticals, Inc. quarterly cash from financing year-on-year change?

Over the past year, AMLX quarterly cash from financing has changed by -$58.00K (-214.81%)

What is Amylyx Pharmaceuticals, Inc. TTM cash from financing?

The current TTM cash from financing of AMLX is $65.82M

What is the all-time high TTM cash from financing for Amylyx Pharmaceuticals, Inc.?

Amylyx Pharmaceuticals, Inc. all-time high TTM cash from financing is $431.79M

What is Amylyx Pharmaceuticals, Inc. TTM cash from financing year-on-year change?

Over the past year, AMLX TTM cash from financing has changed by +$64.54M (+5054.35%)
On this page